Long-Term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation

Long-Term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation

<b>Background</b>: Kidney transplant (KTx) recipients exhibit impaired responses to SARS-CoV-2 vaccination. Correlates of vaccine-induced immunity and risk factors for breakthrough infection are not fully defined. This study evaluated the humoral response trajectories and determinants of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vincenzo Bellizzi, Mario Fordellone, Carmine Secondulfo, Paolo Chiodini, Giancarlo Bilancio
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Vaccines
Subjects:	kidney transplant COVID SARS-CoV-2 mRNA vaccine BNT162b2 hybrid immunity
Online Access:	https://www.mdpi.com/2076-393X/13/6/566
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
by: Weiyi Tang, et al.
Published: (2025-03-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil
by: Fatima de Cássia Evangelista de Oliveira, et al.
Published: (2025-04-01)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
by: Andreina Baj, et al.
Published: (2021-01-01)

Nuclear Factor Erythroid 2-Related Factor 2 and SARS-CoV-2 Infection Risk in COVID-19-Vaccinated Hospital Nurses
by: Stefano Rizza, et al.
Published: (2025-07-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

Effect of recent SARS-CoV-2 infection on anti-spike protein immunoglobulin G II response after BNT162b2 vaccination
by: Daiki Tanno, et al.
Published: (2025-08-01)

Pre-Vaccination Immune Profiles and Responsiveness to Innate Stimuli Predict Reactogenicity and Antibody Magnitude Following mRNA Vaccination
by: Amanda E. Zelkoski, et al.
Published: (2025-07-01)

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273
by: Alejo Erice, et al.
Published: (2025-03-01)

Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis
by: Kyle Fahrbach, et al.
Published: (2025-12-01)

Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy
by: Manuela Di Fusco, et al.
Published: (2024-10-01)

Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report
by: Harukazu Hirano, et al.
Published: (2024-12-01)

COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study
by: Asaf Shemer, et al.
Published: (2025-02-01)

Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar
by: Remy Thomas, et al.
Published: (2025-03-01)

Hybrid immunity of the SARS-CoV-2 vaccine after the third doses in health workers
by: Raúl Montalvo, et al.
Published: (2024-02-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
by: Masliyana Husin, et al.
Published: (2025-01-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
by: Oyeniyi Diya, et al.
Published: (2025-07-01)

Characteristics and outcomes of adverse events after COVID‐19 vaccination
by: Tariq Kewan, et al.
Published: (2021-10-01)

Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection
by: Zdzisława Kondera-Anasz, et al.
Published: (2025-07-01)

Löfgren’s Syndrome Following BNT162b2 mRNA COVID-19 Vaccination and Subsequent Plaque-type Cutaneous Sarcoidosis after its Resolution
by: Masahiro Oka, et al.
Published: (2025-06-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort
by: Jared Sheehan, et al.
Published: (2025-01-01)

Breakthrough Infection After a Primary Series of COVID-19 Vaccination Induces Stronger Humoral Immunity and Equivalent Cellular Immunity to the Spike Protein Compared with Booster Shots
by: Yoshifumi Uwamino, et al.
Published: (2025-07-01)

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”
by: Timothy E. Albertson, et al.
Published: (2025-04-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

COVID-19 vaccination and cerebral small vessel disease progression—A prospective cohort study
by: Yiu Ming Bonaventure Ip, et al.
Published: (2025-02-01)

Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
by: Luis Sarabia de Ardanaz, et al.
Published: (2025-05-01)

Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platformResearch in context
by: Jennifer L. Nguyen, et al.
Published: (2025-01-01)

Side effects of the Pfizer BioNTech vaccine in health workers of a hospital in the southeast of Mexico
by: Jesús Arturo Ruiz-Quiñones, et al.
Published: (2022-09-01)

Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions
by: Ayako Konishi, et al.
Published: (2025-12-01)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
by: Eleonora Francesca Pattonieri, et al.
Published: (2025-02-01)

Letter to the Editor Regarding "Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination" by Albertson et al. 2024
by: Ivan Pourmir, et al.
Published: (2025-04-01)

Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers
by: Sara Maher, et al.
Published: (2024-11-01)

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting
by: Aini Syahida Mat Yassim, et al.
Published: (2025-07-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

COVID-19 vaccination-related attendance at a pediatric emergency department in Singapore among 12- to 18-year old adolescents
by: Nicholas Beng Hui Ng, et al.
Published: (2022-11-01)

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
by: Ho Yu Ng, et al.
Published: (2025-02-01)